Special Issue "Targeted Alpha Therapy (TAT): Progress in Radionuclide Production, Radiochemistry and Applications"
Deadline for manuscript submissions: closed (29 September 2023) | Viewed by 1650
Interests: targeted radionuclide therapy; radiopharmaceuticals; radiolabeling chemistry; nuclear medicine; molecular imaging; valorization and industrial development
2. Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000 Nantes, France
Interests: targeted radionuclide therapy; radiopharmaceuticals; radiolabeling chemistry; nuclear medicine; molecular imaging
In addition to imaging purposes, nuclear medicine offers promising therapeutic options based on the specific irradiation of malignant cells. This application is illustrated by the general concept of targeted radionuclide therapy (TRT) and applied by the use of radiopharmaceuticals which favor radionuclides able to transmit high energy to matter but with low penetration (e.g., b-, a- or Auger electron emitters).
The high linear energy transfer (LET) of a-emitters allows the emitted particle to directly impact the targeted tumor cells with high energy, causing DNA double-strand breaks. Contrary to single-strand DNA breaks induced by b- emitters, these damages have much lower probability of being repaired by cellular mechanisms, leading to cell death. That is why α-emitters are often reported to be more cytotoxic than b--emitters. Additionally, associated with the short path length, the risk of irradiation of healthy surrounding tissues is reduced, which is an advantage in terms of treatment toxicity. These specificities make α-emitters efficient for the treatment of small tumors or disseminated metastases and isolated cancer cells.
Among all the existing α-emitters, only few have suitable properties for potential clinical application. Although accessibility issues have hampered the development of radiopharmaceuticals for targeted alpha therapy (TAT), the better general knowledge acquired over the past few years has made α-emitters increasingly attractive. It is in this context that this Special Issue of Pharmaceuticals will be published, the main idea being to gather contributions in the form of research papers, short communications or review articles discussing radionuclides for TAT and covering production processes, radiochemistry or potential applications (preclinical, clinical and industrial).
Dr. Jean-François Gestin
Dr. Romain Eychenne
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- targeted alpha therapy, α-emitters
- preclinical application
- clinical application
- industrial application